Tedavi edilen primer hipotiroidizmde tirzepatidin kilo kaybı üzerine kısa vadeli etkileri: retrospektif bir çalışma

Öz

Amaç: Bu çalışma, levotiroksin ile tedavi edilen iyi kontrollü primer hipotiroidinin, fazla kilolu veya obez erişkinlerde tirzepatide bağlı kısa dönem vücut kitle indeksi düşüşü ve metabolik yanıtları etkileyip etkilemediğini incelemiştir. Gereç ve Yöntem: Retrospektif, tek merkezli bu çalışmada, tirzepatid başlanan fazla kilolu veya obez erişkinler iki gruba ayrıldı: tiroid hastalığı olmayan bireyler ve stabil levotiroksin tedavisi gören primer hipotiroidili bireyler. Tüm katılımcılara bir ay boyunca haftada bir tirzepatid uygulandı ve standart yaşam tarzı danışmanlığı verildi. Başlangıç ve bir ay sonraki ölçümler vücut kitle indeksi, vücut ağırlığı, açlık kan şekeri, HbA1c, tiroid uyarıcı hormon, serbest tiroksin ve lipid parametrelerini içeriyordu. Grup içi değişiklikler eşleştirilmiş testlerle, grup arası karşılaştırmalar bağımsız testler ve tekrarlı ölçüm analizleri ile değerlendirildi. Bulgular: Her iki grupta da vücut kitle indeksi ve vücut ağırlığında anlamlı düşüş gözlendi. Açlık kan şekeri, HbA1c ve lipid profili iyileşti. Tiroid uyarıcı hormon ve serbest tiroksin düzeyleri stabil kaldı ve gruplar arasında fark bulunmadı. Tiroidle ilgili yan etki görülmedi. Vücut kitle indeksi düşüşü, levotiroksin kullanımından bağımsız olarak benzerdi. Sonuç: İyi kontrol edilen ve levotiroksin ile tedavi edilen primer hipotiroidi, tirzepatide bağlı kısa dönem vücut kitle indeksi düşüşünü veya erken metabolik yararları azaltmamaktadır. Tirzepatid, tiroid hormon replasmanı görenlerde de etkilidir.

Anahtar Kelimeler

• vücut kitle indeksi
• hipotiroidi
• levotiroksin
• lipid metabolizması
• kilo kaybı

Destekleyen Kurum

Bu çalışma ile ilgili herhangi bir finansal kaynaktan yararlanılmamıştır.

Etik Beyan

Çalışma için 17/12/2025 tarihinde Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu'ndan onay alınmıştır. Karar no: 2025/22-13. Bu çalışma, Helsinki Bildirgesi ilkelerine uygun olarak gerçekleştirilmiştir.

Teşekkür

Yok

Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study

Öz

Objective: This study examined whether well-controlled primary hypothyroidism treated with levothyroxine affects short-term body mass index reduction and metabolic responses to tirzepatide in adults with overweight or obesity. Material and Method: In this retrospective, single-center study, adults with overweight or obesity initiating tirzepatide were divided into two groups: individuals without thyroid disease and those with primary hypothyroidism receiving stable levothyroxine. All participants received once-weekly tirzepatide for one month along with standard lifestyle counseling. Measurements at baseline and one month included body mass index, weight, fasting blood glucose, glycated hemoglobin, thyroid-stimulating hormone, free thyroxine, and lipid parameters. Within-group changes were analyzed using paired tests, while between-group comparisons were evaluated with independent tests and repeated-measures analyses. Results: Both groups showed significant decreases in body mass index and weight, with improvements in fasting blood glucose, glycated hemoglobin, and lipid profile. Thyroid-stimulating hormone and free thyroxine remained stable and did not differ between groups. No thyroid-related adverse events occurred. The degree of body mass index reduction was similar regardless of levothyroxine use. Conclusion: Well-controlled primary hypothyroidism treated with levothyroxine does not reduce short-term body mass index loss or early metabolic benefits of tirzepatide, indicating that tirzepatide is effective regardless of thyroid hormone replacement.

Anahtar Kelimeler

• body mass index
• hypothyroidism
• levothyroxine
• lipid metabolism
• weight loss

Destekleyen Kurum

There are no financial funds for this article.

Etik Beyan

Approval for the study was obtained from the Zonguldak Bülent Ecevit University School of Medicine Non-Interventional Clinical Research Ethics Committee on 17/12/2025. Decision no: 2025/22-13. This study was performed in line with the principles of the Declaration of Helsinki.

Teşekkür

None

Kaynakça

1. Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126:1477-1500.
2. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18:e320-350.
3. Yunusoglu O, Turkmen O, Berkoz M, Yildirim M, Yalin S. In vitro anti-obesity effect of Aloe vera extract through transcription factors and lipolysis-associated genes. East J Med. 2022;27:519-528.
4. Yunusoglu O. GLP-1 receptor agonists: mechanisms, clinical applications, and future directions. In: Demirkaya Miloğlu F, Dilek E, editors. Current Studies in Pharmacology. 1st ed. Lyon: Livre de Lyon; 2025. p. 1-30.
5. Kommu S, Sharma PP, Gabor RM. Efficacy and safety of tirzepatide on weight loss in patients without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2025;26:e13961.
6. Khawaji A, Jaly AA, Bakri HA, et al. Weight loss efficacy of tirzepatide compared to placebo or GLP-1 receptor agonists in adults with obesity or overweight: a meta-analysis of randomized controlled trials with ≥20 weeks treatment duration. J Obes. 2025;2025:3442754.
7. Chukir T, Yaghmour M, Almutairi T, Chagoury O, Taheri S. Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: a retrospective case-control study. PLoS One. 2025;20:e0332091.
8. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012;19:408-413.

9. Tee SA, Tsatlidis V, Razvi S. The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf). 2023;99:401-408.
10. Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:927859.
11. Zhang Z, Yang J, Gao L. Implications of glucagon-like peptide-1 receptor agonists on thyroid function and thyroid nodules: a drug target Mendelian randomization and cohort study. Endocr Pract. 2026;32(1):60-66.
12. Humaida S, Manzalji K, Seyam N, Al-Masalmani L. Dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist-associated thyroiditis: a case report of thyroid dysfunction following tirzepatide use. Cureus. 2025;17:e85123.
13. Ross I, Omengan DB, Huang GN, Payumo AY. Thyroid hormone-dependent regulation of metabolism and heart regeneration. J Endocrinol. 2022;252:71-82.
14. Iwen KA, Oelkrug R, Brabant G. Effects of thyroid hormones on thermogenesis and energy partitioning. J Mol Endocrinol. 2018;60:157-170.
15. Kozacz A, Assis GG, Sanocka U, Ziemba AW. Standard hypothyroid treatment did not restore proper metabolic response to carbohydrate. Endocrine. 2021;71:96-103.
16. Biondi B. Subclinical hypothyroidism in patients with obesity and metabolic syndrome: a narrative review. Nutrients. 2023;16:87.
17. Mahdavi M, Amouzegar A, Mehran L, Madreseh E, Tohidi M, Azizi F. Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran Thyroid Study. BMC Endocr Disord. 2021;21:89.
18. Kasagga A, Assefa AK, Amin MN, et al. Dose-dependent efficacy and safety of tirzepatide for weight loss in non-diabetic adults with obesity: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2025;17:e85531.
19. Capuccio S, Scilletta S, La Rocca F, et al. Implications of GLP-1 receptor agonists on thyroid function: a literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels. Biomolecules. 2024;14:687.
20. Sencar ME, Sakiz D, Calapkulu M, et al. The effect of exenatide on thyroid-stimulating hormone and thyroid volume. Eur Thyroid J. 2019;8:307-311.
21. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534-545.
22. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.